Drug liberalization is a drug policy process of decriminalizing or legalizing the use or sale of prohibited drugs. Variations of drug liberalization include: drug legalization, drug re-legalization and drug decriminalization. Proponents of drug liberalization may favor a regulatory regime for the production, marketing, and distribution of some or all currently illegal drugs in a manner analogous to that for alcohol, caffeine and tobacco. Proponents of drug liberalization argue that the legalization of drugs would eradicate the illegal drug market and reduce the law enforcement costs and incarceration rates. They frequently argue that prohibition of recreational drugs—such as cannabis, opioids, cocaine, amphetamines and hallucinogens—has been ineffective and counterproductive and that substance use is better responded to by implementing practices for harm reduction and increasing the availability of addiction treatment. Additionally, they argue that relative harm should be taken into account in the regulation of drugs. For instance, they may argue that addictive or dependence-forming substances such as alcohol, tobacco and caffeine have been a traditional part of many cultures for centuries and remain legal in most countries, though other drugs which cause less harm than alcohol, caffeine or tobacco are entirely prohibited, with possession punishable with severe criminal penalties. Opponents of drug liberalization argue that it would increase the amount of drug users, increase crime, destroy families, and increase the amount of adverse physical effects among drug users. The 1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances made it mandatory for the signatory countries to "adopt such measures as may be necessary to establish as criminal offences under its domestic law" (art. 3, § 1) all the activities related to the production, sale, transport, distribution, etc. of the substances included in the most restricted lists of the 1961 Single Convention on Narcotic Drugs and 1971 Convention on Psychotropic Substances.

About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.
Related courses (9)
BIO-478: Pharmacology and pharmacokinetics
This course introduces the student to the fudamentals of pharmacology, pharmacokinetics and drug-receptor interactions. It discusses also pharmacogenetics and chronopharmacology, to exemplify the chal
CH-332: Medicinal chemistry
Sitting at the crossroad of organic chemistry and medicine, this course outlines how an initial hit compound transitions into a lead candidate, and ultimately a drug, in the modern drug discovery worl
CH-313: Chemical biology
Closely interfacing with bioengineering and medicine, this course provides foundational concepts in applying small-molecule chemical toolsets to probe the functions of living systems at the mechanisti
Show more
Related publications (92)